Prof,
I totally not agree with you on the 3) merging with a ANI for cost effective solution. BPAX should not merge with ANI at all. What BPAX should do is capture the libigel +$200m revenue (4+ million off-label prescriptions) first and with that profits, we can BUYOUT ANI for $20m valuation. That time we can talk about cost effective solution but not now...
I still not happy if get 49.9% with Biosante management themselves accept the same CVRs instead of golden parachute. Again, BPAX worth at least 10X more than ANI. If you talking about fair % ownership, it should be 90% for Bpax and 10% for ANI. Simes and BOD totally mismanagement the company. These crooks and criminals must be punished by lawsuit..
Sorry, for keep saying lawsuits. At this time, I don't see any other solution beside that...
